Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Low Risk Prostate Cancer Clear all
Active, not recruiting No phase listed Observational

Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer

NCT01352429
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Proton Therapy, IMRT
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 24, 2026, 7:19 AM EDT
Active, not recruiting Not applicable Interventional

Stereotactic Ablative Radiation Therapy for Prostate Cancer

NCT05668351
View directory record Official record
Conditions
Prostate Cancer
Interventions
SUPR-SABR treatment
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 24, 2026, 7:19 AM EDT
Terminated Not applicable Interventional

MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca

NCT02564549
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Multiparametric MRI, Gleason's Score 6
Interventions
TRUS-guided biopsy, mpMRI with targeted biopsy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Jul 24, 2026, 7:19 AM EDT
Recruiting Not applicable Interventional

Low-Count Quantitative SPECT for Men Treated With Radium-223

NCT07221825
View directory record Official record
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Low-count quantitative single-photon emission computed tomography imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 24, 2026, 7:19 AM EDT
Recruiting Not applicable Interventional

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

NCT05438563
View directory record Official record
Conditions
Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions
MRI-Guided Transurethral Ultrasound Ablation, Questionnaire Administration, Digital Rectal Examination, Cystoscopy, Biopsy, Bone Scan, PSMA PET Scan, Multiparametric Magnetic Resonance Imaging
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 24, 2026, 7:19 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

NCT05100472
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation
Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 24, 2026, 7:19 AM EDT
Completed Not applicable Interventional Results available

High-Dose Stereotactic Radiation for Prostate Cancer

NCT01664130
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 24, 2026, 7:19 AM EDT
Recruiting Phase 1 Interventional

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

NCT06062745
View directory record Official record
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
Interventions
18F-fluciclovine, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 24, 2026, 7:19 AM EDT
Completed Not applicable Interventional Results available

CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution

NCT00643994
View directory record Official record
Conditions
Prostate Cancer, Prostatic Cancer, Prostate Neoplasms, Prostatic Neoplasms, Cancer of the Prostate
Interventions
CyberKnife Stereotactic Radiosurgery
Radiation
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 24, 2026, 7:19 AM EDT
Completed Not applicable Interventional Results available

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer

NCT00706966
View directory record Official record
Conditions
Nonmalignant Neoplasm, Prostate Cancer
Interventions
dutasteride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Jul 24, 2026, 7:19 AM EDT
Active, not recruiting Phase 2 Interventional

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

NCT03436654
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Abiraterone Acetate, Prednisone, GnRH agonist/antagonist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 24, 2026, 7:19 AM EDT
Completed Phase 3 Interventional

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

NCT00003674
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Veno-occlusive Disease
Interventions
dalteparin, standard therapy
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
19
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 24, 2026, 7:19 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jul 24, 2026, 7:19 AM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

NCT06060587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ADT, Abiraterone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 24, 2026, 7:19 AM EDT
Recruiting Phase 2 Interventional

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

NCT06145633
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Single Photon Emission Computed Tomography, Vorinostat
Procedure · Other · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 24, 2026, 7:19 AM EDT
Completed Phase 1 Interventional

A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer

NCT01187485
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androderm® 2.5mg, Androderm® 5.0mg, Androderm® 7.5mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jul 24, 2026, 7:19 AM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 24, 2026, 7:19 AM EDT
Terminated Not applicable Interventional Results available

Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer

NCT00619515
View directory record Official record
Conditions
Prostate Cancer
Interventions
questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
Other · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Cleveland, Ohio • Westlake, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Jul 24, 2026, 7:19 AM EDT
Active, not recruiting Not applicable Interventional

SpaceIT Hydrogel System for Perirectal Spacing

NCT06451614
View directory record Official record
Conditions
Prostate Cancer
Interventions
SpaceIT Hydrogel System, Commercially available Boston Scientific Spacer
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Laguna Hills, California • Los Angeles, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 24, 2026, 7:19 AM EDT
Completed Not applicable Interventional

Pilot Study on Focal Prostate Radio-Frequency Ablation

NCT01423006
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radio-Frequency Ablation (RFA) ENCAGE™
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Jul 24, 2026, 7:19 AM EDT
Terminated Phase 2 Interventional Results available

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

NCT01650350
View directory record Official record
Conditions
Melanoma, Prostate Cancer, Renal Cancer
Interventions
Naltrexone
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 24, 2026, 7:19 AM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00009750
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, monoclonal antibody m170, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody m170, yttrium Y 90 monoclonal antibody m170
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 24, 2026, 7:19 AM EDT
Completed Not applicable Interventional Results available

Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study

NCT05764005
View directory record Official record
Conditions
Prostate Cancer
Interventions
web-based tool (MAP- Management of Active surveillance in Prostate Cancer), MUSIC website
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
55 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 24, 2026, 7:19 AM EDT
Completed Not applicable Interventional Results available

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

NCT00643617
View directory record Official record
Conditions
Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms, Cancer of the Prostate
Interventions
CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk
Radiation
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
18
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 24, 2026, 7:19 AM EDT